Any content you receive is for information purposes only. Always conduct your own research.
*Sponsored
Market Crux Just Put VolitionRx Limited (NYSE: VNRX) On
This Morning’s Watchlist—Thursday, July 30, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Pull Up VNRX While It’s Still Early… July 30, 2026 Dear Reader, Two companies. One agreement. Very different sizes. The first has been building diagnostics equipment since 1968. Its analyzers run in hospital labs across more than 190 countries and regions. That is Sysmex Corporation. The second is worth about $7Mn and employs 67 people. That is VolitionRx Limited (NYSE American: VNRX). On June 17, 2026, they signed a collaboration agreement. Read that again. The manufacturer selling into 190 countries signed with the 67-person company. Agreements rarely run in that direction, and Sysmex has its pick of partners. So why this one? Because its own engineers had already put Volition's Nu.Q NETs H3.1 assay onto the Sysmex platform and watched it hold up. The commitment followed the result, not a pitch. The two are optimizing it together now. Volition's entire plan is to license its tests to partners who already own the machines and the hospital relationships. Before June 17, that plan lived on a slide. And here is what most of the market has not caught up to yet. There is a $5Mn contractual payment waiting on a study already sitting with peer reviewers. That single payment is worth more than the entire company at current levels. That is why (VNRX) leads our report this morning. The bell is about 90 minutes out, and there is more below. 
But keep in mind, (VNRX) has fewer than 7M shares listed as available to the public. That is a small number. When floats get this tight, the potential exists for big swings once demand shifts. Now look at where it sits. (VNRX) is currently below $1 and drawing little attention. That combination has pushed the near-term momentum readings into rare territory. Barchart shows the Relative Strength Index on (VNRX) at 15.49 on a 9-day basis. 21.92 on 14-day. 26.61 on 20-day. Anything under 30 is what most technical readers call oversold. Some frameworks tie readings like these to the setup for a potential trend reversal. Several Analysts Have Taken Notice
Maxim Group analyst Michael Okunewitch has a bullish rating on VNRX with a $4 target. And according to TipRanks, Justin Walsh at Jones raised his target on VNRX from $3 to $24, which suggests significant upside potential from its recent range. Revenue is moving too. Volition reported first-quarter 2026 revenue near $1Mn. That is a 300% increase over the same period last year. And Sysmex was not the only signed development to land here this summer. On July 7, 2026, Volition released real-world data on its Nu.Q Cancer assay. The work showed prognostic value in newly diagnosed lung cancer patients. It was produced alongside clinicians at Hospices Civils de Lyon. See full story here.
Clinical certification at that hospital system is already complete. A reimbursement submission in France is being prepared, with routine clinical use targeted before year end. That is the surface. Here is the foundation underneath it. What VNRX Actually Does
VolitionRx Limited builds blood tests. That is the simple version. The longer one: it is a multi-national epigenetics company developing blood-based tests to detect and monitor cancer, plus diseases tied to NETosis, including sepsis. Research and development runs out of Belgium. There is an innovation lab and office in the United States, and an office in London. Headquarters sit in Henderson, Nevada. Roughly 67 people work there. Now here is the part that matters. Everything this company sells comes off one proprietary platform. It is called Nucleosomics. It measures nucleosomes and their epigenetic modifications as they circulate in your blood. From that single core, Volition built four separate commercial pillars. Four clinical problems. One research engine behind all of them. Pillar one is the furthest along. Nu.Q Vet already sells in more than 20 countries. The canine cancer test is live and generating revenue today. A feline version is next. It targets lymphoma, the most common cancer in cats. Volition submitted it for peer review after the assay detected 86% of feline lymphomas at 97% specificity. See full story here.
Publication is expected to unlock a $5Mn contractual milestone payment. Management also believes a feline test could roughly double what it can address in companion animal health. Pillar two is already in hospitals. Nu.Q NETs is CE-marked and clinically available across Europe. The market behind it runs an estimated $3.8Bn. Pillar three is close. Nu.Q Cancer is moving toward routine clinical use in lung cancer in France. Pillar four is the largest. Capture-Seq is the earliest-stage program, a liquid biopsy method the company estimates addresses roughly $23Bn a year. So where does the money come from today? Four places. Assay sales. Research services through Nu.Q Discover. Contractual milestone payments. And non-dilutive funding from Walloon Region agencies in Belgium. But licensing is where management expects the step change. Upfront payments. Milestones. Royalties from large diagnostics groups. And those conversations are already happening. The company has confirmed active discussions with more than a dozen of the world's leading diagnostics and liquid biopsy companies. Several are at the technical evaluation stage already. VNRX Is Aiming At $27Bn With 67 Employees
Liquid biopsy is one of the few corners of diagnostics where clinical need and reimbursement are moving at the same time. The economics are simple. A blood draw that catches disease earlier costs a fraction of the imaging, biopsy, and late-stage treatment it replaces. So what has held the field back? Not the science. The cost. Sequencing-based approaches stay expensive enough that broad screening is hard to justify outside high-risk groups. Volition sits in that sector differently, in two ways. First, it is platform-based, not indication-based. Most companies this size build one test for one disease. One regulatory path. One point of failure. Volition's nucleosome chemistry covers cancer detection, sepsis triage, chronic inflammatory disease, and veterinary oncology off the same science. Several paths forward. One research budget. Second, it stays capital-light commercially. The company estimates combined addressable markets above $27Bn across its pillars. The sepsis side deserves its own look. Published estimates put global sepsis cases near 166M a year. Sepsis-related deaths accounted for 31.5% of all global deaths in 2021. Volition's Nu.Q NETs assay is already inside DETECSEPS, a government-backed program in France worth roughly $7.3Mn. It starts in the third quarter of 2026. What Landed At VNRX While Nobody Was Looking
July 7, 2026
Lung Cancer Data Lands With France's Second
Largest Hospital System
Volition released clinical data showing the prognostic value of its Nu.Q Cancer assay in newly diagnosed lung cancer patients. The work was produced with researchers at Hospices Civils de Lyon. Clinical certification at HCL is already complete. A reimbursement submission in France is being prepared. See full story here.
June 17, 2026
A Global Diagnostics Manufacturer Signs On
Volition announced its collaboration with Sysmex (TYO: 6869) to optimize the Nu.Q NETs H3.1 assay on the Sysmex platform. The agreement followed successful transfer of the assay onto that system. See full story here.
June 3, 2026
New Patent Filing Extends Nu.Q NETs Into Outbreak Settings
Volition filed a new patent application covering use of its Nu.Q NETs test for triage and treatment monitoring in outbreak settings. The company stated it is seeking strategic partners to deploy the platform in affected regions. See full story here.
May 27, 2026
One Update, Four Pillars, $27Bn In Addressable Markets
A consolidated corporate update detailed 300% first quarter revenue growth. It also covered progress toward the $5Mn veterinary milestone, inclusion of Nu.Q NETs in the DETECSEPS program, and active licensing discussions with more than a dozen global diagnostics leaders. See full story here.
May 6, 2026
A $5Mn Payment Now Sits With Peer Reviewers
Volition submitted for peer review a clinical manuscript reporting the accuracy of its Nu.Q Vet feline prototype assay in detecting lymphoma in cats. Publication is expected to unlock a $5Mn contractual milestone payment. See full story here.
April 29, 2026
From Hospital Lab To Finger Prick
Volition reported successful detection of nucleosomes in capillary blood from critically ill sepsis patients using a lateral flow prototype. The finger-prick format could extend testing to the bedside, the emergency room, and eventually the home. See full story here. Why VNRX Has Our Full Focus This Morning
—Thursday, July 30, 2026… 1. A Giant Signed: A diagnostics manufacturer selling in more than 190 countries put its name on an agreement with VNRX, which means the technology cleared a serious technical review first. 2. Tight Share Count: With fewer than 7M shares listed as available to the public, VNRX’s small float could have the potential to witness big swings if demand begins to shift. 3. News Keeps Coming: Six separate announcements have come out of (VNRX) in ten weeks, a heavy pace for a company this size. 4. Wide Target Spread: Analyst targets on VNRX run from $4 up to $24 according to TipRanks, and the lowest of them still sits above where it closed Monday. 5. Revenue Climbing: First-quarter revenue at VNRX reached roughly $1Mn, four times what the company recorded a year earlier. 6. Four Shots Total: One platform gives VNRX four separate programs, so a delay in any single area does not stall the rest. 7. Hospital Cleared It: A major French hospital system has finished certifying the cancer test from VNRX, and reimbursement paperwork is the next step. Pull Up VNRX While It’s Still Early…
Market Crux looks for companies that have done more than the market has noticed. VNRX fits this mold. It has fewer than 7M shares available to the public. Its market value sits near $7Mn. It just signed an agreement with one of the largest blood test manufacturers in the world. Revenue is four times what it was a year ago. And a $5Mn payment is waiting on a study that is already with reviewers. That is why VNRX is topping our watchlist this morning. Take a look while it’s still early, and watch for my next update. Sincerely, Gary Silver
Managing Editor,
Market Crux |
0 التعليقات:
إرسال تعليق